New York and Suzhou, China – September 20, 2026 -- Accro Bioscience Inc. has dosed its first patient in a Phase IIb trial testing AC-101, a selective RIPK2 inhibitor, in patients with moderate-to-severe ulcerative colitis (UC).

Suzhou – – September 16, 2026 -- Accro Bioscience said AC-101 tablets have been included in the National Medical Products Administration's Center for Drug Evaluation (CDE) "Caring Plan-Extension" pilot program, targeting Blau syndrome as the proposed indication, with the public notice period closing September 11, 2026.